Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study.
Stavudine (d4T) has been associated with lipoatrophy and hyperlactatemia. In recent studies, d4T has also been related to both hypercholesterolemia and hypertriglyceridemia. Replacing d4T with another nucleoside analogue such as abacavir (ABC) may reduce lactate levels and improve lipoatrophy in the long term. However, the impact of this strategy on the lipid profile is still unclear. In a prospective and randomized study, fasting lipids were examined over 48 weeks in 112 subjects on d4T regimens, 49 of whom replaced d4T with ABC. The substitution of ABC for d4T was found to be safe and provided a reduction in both LDL cholesterol and the total cholesterol (TC)/HDLc ratio, which might impact favorably on cardiovascular risk.
García-Benayas
Teresa
T
Service of Infectious Diseases, Hospital Carlos III, 28035 Madrid, Spain.
Blanco
Francisco
F
Alcolea
Antonio
A
Cruz
Juan José De La
JJ
González-Lahoz
Juan
J
Soriano
Vincent
V
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008055:Lipids / Q000097:blood; D008060:Lipodystrophy / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D008055:Lipids; D018119:Stavudine; D000099227:Abacavir